Cytokine Regulation of the Acute-phase Protein Levels in Multiple Myeloma
Overview
Authors
Affiliations
Background: Interleukin (IL) 6 has an important role in the regulation of acute-phase proteins (APPs) during an acute-phase response. We studied IL-6 and other cytokines to determine if they regulate serum APP levels in the same way under the condition of the aberrant, long-lasting 'acute-phase response' that occurs in patients with chronic inflammation and cancer.
Methods: Serum levels of nine positive APPs [CRP, SAA, C1-INH, Bf, C5, C8, C9, alpha 1-acidic glycoprotein (AGP) and haptoglobin] and two negative APPs [transferrin and alpha 2-HS glycoprotein (AHSG)] were measured using immunochemical methods in 59 multiple myeloma patients and in 72 healthy control subjects. Serum IL-6 and tumour necrosis factor (TNF) alpha levels were determined by bioassays.
Results: IL-6 was negatively correlated with five out of nine (C1-INH, C8, C9, AGP and haptoglobin) positive APPs but positively correlated with C-reactive protein (CRP). When patients with high and low IL-6 serum concentration were compared, CRP levels were higher, AGP and haptoglobin levels were lower in the high- than in the low-L-6 group, whereas no significant difference between the two groups was found in levels of the other positive and negative APPs. TNF-alpha levels were negatively correlated with transferrin and AHSG levels. No difference in the levels of positive APPs was observed between patients with low and high TNF-alpha serum concentration. By contrast, levels of both transferrin and AHSG were significantly lower in the high- than in the low-TNF-alpha group.
Conclusions: These findings indicate that, except for regulation of the negative APPs by TNF-alpha, the mechanism of APP regulation is different under the conditions of the short-term and the chronic, long-lasting 'acute-phase reaction'.
Elevated extracellular trap formation and contact system activation in acute leukemia.
Kim T, Gu J, Jung H, Koh Y, Kim I, Kim H J Thromb Thrombolysis. 2018; 46(3):379-385.
PMID: 30099724 DOI: 10.1007/s11239-018-1713-3.
De Buck M, Gouwy M, Wang J, Van Snick J, Opdenakker G, Struyf S Curr Med Chem. 2016; 23(17):1725-55.
PMID: 27087246 PMC: 5405626. DOI: 10.2174/0929867323666160418114600.
Acute-phase proteins: As diagnostic tool.
Jain S, Gautam V, Naseem S J Pharm Bioallied Sci. 2011; 3(1):118-27.
PMID: 21430962 PMC: 3053509. DOI: 10.4103/0975-7406.76489.
Zahlten-Hinguranage A, Goldschmidt H, Cremer F, Egerer G, Moehler T, Witte D Br J Cancer. 2006; 95(7):782-7.
PMID: 16969356 PMC: 2360525. DOI: 10.1038/sj.bjc.6603329.
Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
Kuku I, Bayraktar M, Kaya E, Erkurt M, Bayraktar N, Cikim K Mediators Inflamm. 2005; 2005(3):171-4.
PMID: 16106104 PMC: 1526466. DOI: 10.1155/MI.2005.171.